FDA Seeks Input to Advance Botanical Drug Development

Silver Spring, Maryland, USA, September 3, 2026

FDA Targets Challenges in Botanical Drug Development

Botanical drug products are medicines derived from plant materials and can contain complex mixtures of naturally occurring constituents. Their development can present scientific and regulatory challenges that differ from those encountered with conventional single-molecule pharmaceutical products. Variability in botanical raw materials, manufacturing processes, chemical composition and biological activity can create additional requirements for quality control, characterization, consistency and clinical evaluation. The FDA’s latest initiative seeks stakeholder perspectives on how these challenges can be addressed while supporting the development of potentially valuable botanical medicines. The agency’s RFI provides an opportunity for industry and scientific stakeholders to identify areas where existing approaches may create development barriers and where regulatory processes could potentially be improved. For pharmaceutical developers, the discussion is particularly relevant because successful botanical drug development requires control across the entire product lifecycle, from plant sourcing and cultivation through extraction, manufacturing, analytical testing and clinical development. Establishing reproducible manufacturing processes and appropriate specifications can be essential to demonstrating that a botanical product has consistent quality and predictable therapeutic characteristics. The FDA’s request for information therefore has potential implications for CMC development, analytical characterization, clinical trial design and regulatory submissions involving botanical drug candidates.

FDA and EMA to Discuss Botanical Medicines

The FDA’s initiative also includes international regulatory engagement. The agency recently collaborated with the Reagan-Udall Foundation for the FDA on a roundtable focused on challenges and opportunities associated with botanical drug development. In addition, the FDA and the European Medicines Agency (EMA) are scheduled to hold a joint workshop on September 25, 2026, addressing regulatory considerations for herbal medicinal and botanical drug products intended for medicinal use. The planned FDA-EMA workshop could provide an important forum for comparing regulatory perspectives and discussing approaches to botanical medicines across major pharmaceutical markets. Greater alignment in scientific and regulatory expectations could potentially help developers understand requirements for products intended for international development and commercialization. For the biopharmaceutical sector, regulatory clarity is particularly important for botanical products because their complex composition can require specialized analytical strategies. Developers may need to establish appropriate identity, purity, strength, composition and quality specifications, while demonstrating that manufacturing processes consistently produce material suitable for clinical and commercial use. The FDA’s public consultation could therefore help identify practical areas where scientific advances and regulatory modernization can support responsible development without weakening product-quality expectations.

Public Comments Could Shape Future Regulatory Policy

The FDA is encouraging stakeholders to provide comments on the opportunities and challenges facing botanical drug development. Public input can help the agency understand where developers encounter scientific, technical or regulatory obstacles and where additional guidance, research or policy development could facilitate innovation. Importantly, the announcement does not represent approval of any specific botanical drug and does not establish a new marketing pathway by itself. Instead, it is an information-gathering exercise that could contribute to future regulatory thinking and potential changes in how botanical drug products are developed and evaluated. The initiative comes as interest continues to grow in plant-derived therapeutics and complex natural-product medicines. Botanical sources have historically contributed important pharmaceutical compounds, while modern analytical technologies are providing researchers with improved tools to characterize complex mixtures and investigate their mechanisms of action. For companies developing botanical medicines, the FDA’s RFI represents an opportunity to provide evidence-based feedback on regulatory science, manufacturing consistency, analytical methods, clinical development and product characterization. The agency’s engagement with stakeholders, together with its upcoming collaboration with European regulators, could help shape the future regulatory environment for botanical drug products. The September 3 announcement therefore represents an important pharmaceutical regulatory development, potentially influencing how botanical medicines are researched, manufactured, tested and brought through the drug-development pipeline in the United States.

Source: FDA press release